FBRX
Forte Biosciences, Inc.
$20.58
-1.67 (-7.51%)
At close · Jul 8
Market Cap
$509.60M
Shares
13,885,668
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$20.58
Open$21.97
Day$20.20–22.48
52W$9.10–35.80
Avg vol 30d389K
Short int1.5M · 10.5% float · 5.1d
Short vol43%
Last earningsMay 10, 2021
DataJan 2020–Jul 2026
Filing10-Q · May 11
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−10%
below
Price vs 50-day avg
−3%
below
RSI (14)
52
neutral
MACD trend
Positive
52-week position
43%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+31%
trailing
6-month return
−37%
trailing
YTD return
−25%
this year
Relative strength
−44%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $21 › 200d $23 — 200d above 50d
Institutional flow
Accumulating
+17% holders QoQ · +20 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.52% of float · ▲ +6.8% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
69 holders — near 1-yr high, broad support
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+61%
Y/Y
Free cash flow
$-51.0M
Balance sheet
$77.0M
net cash
Quant / Vol
risk profile
Volatility
96%
annualized · 1-yr
Max drawdown
−56%
past year
ATR
8.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−10%
Bearish
Price vs 50-day avg
−3%
Neutral
RSI (14)
52
Neutral
MACD trend
Positive
Bullish
52-week position
43%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $21 › 200d $23 — 200d above 50d
Institutional flow
Accumulating
+17% holders QoQ · +20 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.52% of float · ▲ +6.8% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
69 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $9
Now $21 · 43%
52-wk high $36
vs 200-day avg -10%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FBRX
this stock
Forte Biosciences, Inc.
|
$509.60M | -24.5% | -99.8% | — | 10.5% |
|
ONC
BeOne Medicines Ltd.
|
$437.67B | -0.6% | +22179.2% | 890.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.01B | +9.9% | +46.2% | 29.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.03B | -14.0% | +20.8% | 16.3 | 3.2% |
|
ARGX
Argenx SE
|
$56.84B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FBRX | -3.2% | +31.3% | -36.7% | -3.2% | -24.5% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -3.0% | +30.5% | -44.1% | -3.0% | -33.8% |